CoChat

Gut Microbiome Signatures Are Predictive of Infectious Risk Following Induction Therapy for Acute Myeloid Leukemia

Open access

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

Background: The majority of studies that provide insights into the influence of the microbiome on the health of hematologic malignancy patients have concentrated on the transplant setting. Here, we sought to assess the predictive capacity of the gastrointestinal microbiome and its relationship to infectious outcomes in patients with acute myeloid leukemia (AML). Methods: 16s rRNA-based analysis was performed on oral swabs and stool samples obtained biweekly from baseline until neutrophil recovery following induction chemotherapy (IC) in 97 AML patients. Microbiome characteristics were correlated with clinical outcomes both during and after IC completion. Results: At the start of IC, higher stool Shannon diversity (hazard ratio [HR], 0.36; 95% confidence interval [CI], .18–.74) and higher relative abundance of Porphyromonadaceae (HR, 0.36; 95% CI, .18–.73) were associated with increased probability of remaining infection-free during neutropenia. A baseline stool Shannon diversity cutoff of <2 had optimal operating characteristics for predicting infectious complications during neutropenia. Although 56 patients received therapy >72 hours with a carbapenem, none of the patients had an infection with an extended spectrum β-lactamase–producing organism. Patients who received carbapenems for >72 hours had significantly lower α-diversity at neutrophil recovery (P = .001) and were approximately 4 times more likely to have infection in the 90 days following neutrophil recovery (HR, 4.55; 95% CI, 1.73–11.93). Conclusions: Our results suggest that gut microbiome evaluation could assist with infectious risk stratification and that improved targeting of antibiotic administration during IC could decrease subsequent infectious complications in AML patients. Baseline microbiome diversity is a strong independent predictor of infection during acute myeloid leukemia induction chemotherapy (IC) among clinical and microbiome covariates. Higher baseline levels of Porphyromonadaceae appear protective against infection, while carbapenem use is associated with consequences to the microbiome and infection susceptibility post-IC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/ciz777

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. 30. Alkek Center for Metagenomics and Microbiome Research. ATIMA (Agile toolKit for Inclusive Microbial Analyses) 2019. Available at: https://cmmr.shinyapps.io/atima2/ [Google Scholar]

Cited by

See all 158

Metadata

Authors
Galloway-Peña, J. R., Shi, Y., Peterson, C. B., Sahasrabhojane, P., Gopalakrishnan, V., Brumlow, C. E., Daver, N. G., Alfayez, M., Boddu, P. C., Khan, M. A. W., Wargo, J. A., Do, K.-A., Jenq, R. R., Kontoyiannis, D. P., & Shelburne, S. A.
Affiliations
  • Department of Genomic Medicine, Houston, Texas, USA
  • Department of Biostatistics, Houston, Texas, USA
  • Department of Infectious Disease, Infection Control, and Employee Health, Houston, Texas, USA
  • Department of Surgical Oncology, Houston, Texas, USA
  • The University of Texas MD Anderson Cancer Center (US)
  • Yale University (US)
Corresponding author
Shelburne, Samuel A
Venue
Clinical Infectious Diseases
Published
2019-08-22
Volume
71
Issue
1
Pages
63-71
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2969463435
Cited by
140
References
50
Citations by year
2026: 24 · 2025: 32 · 2024: 18 · 2023: 24 · 2022: 14 · 2021: 20 · 2020: 8
FWCI
3.48
Type
journal article
Language
en
Open access
Locations
  • Clinical Infectious Diseases (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • MD Anderson Cancer Center
  • Anderson Odyssey Fellowship Program
  • National Institute of Allergy and Infectious Diseases (1 K01 AI143881-01)
  • National Cancer Institute (P30CA016672, R01 CA219896-01A1)
  • United States-Israel Binational Science Foundation (201332)
  • Kennedy Memorial Foundation (0727030)
  • American Association for Cancer Research Stand Up To Cancer (SU2C-AACR-IRG-19-17)
  • Department of Defense (W81XWH-16-1-0121)
  • Andrew Sabin Family Fellows Program
  • Texas 4000 Distinguished Professorship
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Keywords
gut microbiota, acute myeloid leukemia, induction chemotherapy, infectious disease risk, neutropenia, Porphyromonadaceae, microbial diversity, carbapenem use, extended-spectrum beta-lactamase, infection prediction, antibiotic stewardship, neutrophil recovery
MeSH terms
Gastrointestinal Microbiome, Feces, Humans, RNA, Ribosomal, 16S, Leukemia, Myeloid, Acute, Induction Chemotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.